At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Akeso Biopharma took center stage with groundbreaking Phase III results that could redefine the treatment of squamous non-small cell lung cancer (sq-NSCLC). The study, known as HARMONi-6, positioned Akeso’s PD-1/VEGF bispecific antibody, ivonescimab, against the established 'gold standard' of PD-1 inhibitors combined with chemotherapy. This head-to-head trial represents a bold attempt by a Chinese biotech firm to disrupt the dominant immunotherapy paradigm that has governed lung cancer treatment for nearly a decade.
The results revealed a 34% reduction in the risk of death for patients treated with ivonescimab plus chemotherapy compared to the control group. Median overall survival reached 27.9 months, a 4.2-month extension over the 23.7 months seen in the tislelizumab arm. These figures are statistically significant and represent the first time a global Phase III study has achieved dual positive results in both overall survival and progression-free survival in this specific setting. The data suggests that bispecific antibodies—which target two different pathways simultaneously—may offer a superior iterative leap over first-generation checkpoint inhibitors.
Despite the enthusiasm at the ASCO Plenary Session, the market response remained measured, reflecting deep-seated nuances in the data. While the 24-month survival rate for the ivonescimab group reached a promising 64.7%, analysts pointed out that the median follow-up period has not yet fully matured to cover the entire patient survival cycle. Furthermore, the study population was heavily skewed toward male smokers within China, raising questions about whether these results can be replicated across broader global demographics, particularly among non-smokers and female patients.
Safety profiles also remain a focal point for institutional investors and clinicians alike. The ivonescimab group reported a higher incidence of Grade 3 or higher bleeding events at 2.6%, compared to just 0.8% in the control arm—a side effect often associated with VEGF inhibition. As Akeso moves toward regulatory review in China, the 'end game' for ivonescimab will depend on its performance in upcoming global trials and its ability to prove that its survival benefit holds steady across diverse ethnic and age groups, including those over 65 who showed less pronounced gains in this initial readout.